
    
      This is a multi-center, open-label, randomized, Phase 2 study of IONIS-GHR-LRx in up to 40
      participants with acromegaly. Participants will be randomized to 1 of 3 treatment groups to
      receive a single dose of IONIS GHR-LRx monthly for 73 weeks. At the end of 73 weeks,
      participants will enter a 14-week post-treatment (PT) evaluation period.
    
  